<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963064</url>
  </required_header>
  <id_info>
    <org_study_id>JAS-BMT-CP-001</org_study_id>
    <nct_id>NCT02963064</nct_id>
  </id_info>
  <brief_title>JSP191 Antibody Targeting Conditioning in SCID Patients</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jasper Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jasper Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody&#xD;
      conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency&#xD;
      undergoing blood stem cell transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody&#xD;
      conditioning regimen, known as JSP191, in patients with SCID undergoing blood stem cell&#xD;
      transplantation. Blood Stem Cell transplantation offers the only potentially curative therapy&#xD;
      for SCID.&#xD;
&#xD;
      The biological conditioning regimen, JSP191, is an antibody that binds to CD117. CD117 is the&#xD;
      receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is&#xD;
      critical for survival and maintenance of blood forming stem cells. The binding of JSP191 to&#xD;
      CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the&#xD;
      absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently&#xD;
      occupying the bone marrow niches in SCID patients are depleted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">August 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Safety and tolerability of JSP191 as conditioning therapy in SCID patients undergoing HCT: adverse events</measure>
    <time_frame>Up to 5 years post Donor Cell Transplant (28 days dose limiting toxicity period)</time_frame>
    <description>The number of subjects experiencing dose limiting toxicities including adverse events and serious adverse events will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients</measure>
    <time_frame>Up to 24 weeks post Donor Cell Transplant</time_frame>
    <description>To enable engraftment of allogeneic CD34+ hematopoietic cells, as determined by CD15+ donor myeloid chimerism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Efficacy of JSP191 as conditioning therapy in SCID patients</measure>
    <time_frame>Weeks 36-104 post Donor Cell Transplant</time_frame>
    <description>To enable immune reconstitution, as determined by the production of naive T cells</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>SCID</condition>
  <arm_group>
    <arm_group_label>Blood Stem Cell Transplant w/ anti-CD117 conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will enroll two groups: Group A: previously transplanted SCID patients; Group B: newly diagnosed SCID. The study plans to assess JSP191 in different dose cohorts. Patients will receive a single dose of intravenous JSP191 antibody followed by monitoring for antibody clearance. Once the antibody has cleared below a certain level, patients will receive stem cell transplant and be monitored for hematopoietic recovery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humanized anti-CD117 Monoclonal Antibody (JSP191)</intervention_name>
    <description>Procedure: single intravenous infusion of JSP191 antibody</description>
    <arm_group_label>Blood Stem Cell Transplant w/ anti-CD117 conditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        All patient groups must have:&#xD;
&#xD;
          1. Typical SCID as defined by Primary Immune Deficiency Treatment Consortia including but&#xD;
             not limited to the following subtypes:&#xD;
&#xD;
               1. T-, B+, NK-: IL-2Rcγ deficient, JAK3-deficient&#xD;
&#xD;
               2. T-, B-, NK+: RAG1/2 deficient, Artemis-deficient&#xD;
&#xD;
               3. T-, B+, NK+: IL7Rα deficient, CD3 subunit deficient, CD45 deficient OR Variant&#xD;
                  SCID with absent or low T cell function, Omenn syndrome, Leaky SCID, Reticular&#xD;
                  dysgenesis, Adenosine deaminase deficiency, and Purine nucleoside phosphorylase&#xD;
                  deficiency may be included after consultation with the medical monitor.&#xD;
&#xD;
          2. Patients with human leukocyte antigen (HLA) matched related or unrelated donors&#xD;
&#xD;
          3. Adequate end organ function as defined in study protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any acute or uncontrolled infections&#xD;
&#xD;
          2. Patients receiving any other investigational agents, or concurrent biological,&#xD;
             chemotherapy, or radiation therapy&#xD;
&#xD;
          3. Patients with active malignancies&#xD;
&#xD;
          4. Active GVHD within 6 months prior to enrollment, or on immunosuppressive therapy for&#xD;
             GVHD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajni A. Agarwal-Hashmi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lucile Packard Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher C. Dvorak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff's Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph H. Oved, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theodore B. Moore, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Mattel Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharat Chandra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christen L Ebens, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry L Malech, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shanmuganathan Chandrakasan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Healthcare of Atlanta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Jasper Therapeutics, Inc.</last_name>
    <phone>650-549-1270</phone>
    <email>ClinicalTrials@JasperTherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Mattel Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Vargas</last_name>
      <phone>310-871-0614</phone>
      <email>andresvargas@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore B. Moore, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Merkel, RN</last_name>
      <phone>650-721-0644</phone>
      <email>merkel@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Rajni A. Agarwal-Hashmi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff's Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenny Truong</last_name>
      <phone>415-502-2080</phone>
      <email>kenny.truong@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher C. Dvorak, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hanrahan</last_name>
      <phone>404-785-9831</phone>
      <email>Rebecca.Hanrahan@choa.org</email>
    </contact>
    <contact_backup>
      <last_name>Shanmuganathan Chandrakasan, M.D.</last_name>
      <phone>404-727-8877</phone>
      <email>shanmuganathan.chandrakasan@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Graham, RN, BSN, MSA</last_name>
      <phone>301-761-6732</phone>
      <email>pamela.graham@nih.gov</email>
    </contact>
    <investigator>
      <last_name>Harry L. Malech, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Griffin</last_name>
      <email>griffint@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Matzke, RN</last_name>
      <phone>612-624-5831</phone>
      <email>matzk042@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christen L. Ebens, M.D., MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgia Flynn</last_name>
      <email>flynng@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Joseph H. Oved, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Wilhelm</last_name>
      <phone>513-803-1102</phone>
      <email>jamie.wilhelm@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Sharat Chandra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunodeficiency</keyword>
  <keyword>Pediatric</keyword>
  <keyword>SCID</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>GVHD</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Chimerism</keyword>
  <keyword>Transplant</keyword>
  <keyword>BMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data collected is for future publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

